title: [Prostate cancer screening].
abstract: Prostate cancer has become the most frequent cancer and the second cause of cancer mortality in men. This public health problem is becoming increasingly important due to the increasing life expectancy. At the present time, prostate cancer will be discovered in one in every eight men during their lifetime. Prostate cancer represents 25% of all new cases of male cancers. Prostate cancer screening is designed to detect early stage, asymptomatic prostate cancer, as the patient's chances of cure are higher when the cancer is diagnosed at an early stage. The conclusions of the ANAES evaluation in 1998 did not recommend mass screening for prostate cancer. Several international prospective randomized studies based on serum PSA assay, sometimes associated with digital rectal examination, are currently underway. France is participating in the European ERSPC study (European Randomized Study of Screening for Cancer Prostate) and is organizing a national study on high-risk populations. While waiting for the final results of these studies, a recommendation needs to be proposed to inform general practitioners and specialists about optimal use of the currently available tests. Based on the conclusions of its oncology committee (composed of urologists, medical oncologists, radiotherapists, pathologists and radiologists), the Association Française d'Urologie proposes a recommendation concerning prostate cancer screening and defines its modalities, especially concerning the target population, screening tests and the information given to men before screening. The Association Française d'Urologie recommends prostate cancer screening by PSA assay (prostate specific antigen) and digital rectal examination annually between the ages of 50 and 75 years, and from the age of 45 years in men with a family or ethnic risk. If total PSA is above the normal value of the test or if digital rectal examination is abnormal, referral to a urologist is recommended. Information concerning the limits, benefits and risks of screening and the available treatment options must be given before performing these examinations.
authors.forename: Arnauld
authors.initials: A
authors.lastname: Villers
authors.forename: Xavier
authors.initials: X
authors.lastname: Rébillard
authors.forename: Michel
authors.initials: M
authors.lastname: Soulié
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Davin
authors.forename: Patrick
authors.initials: P
authors.lastname: Coloby
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Moreau
authors.forename: Arnaud
authors.initials: A
authors.lastname: Mejean
authors.forename: Jacques
authors.initials: J
authors.lastname: Irani
authors.forename: Christian
authors.initials: C
authors.lastname: Coulange
authors.forename: Philippe
authors.initials: P
authors.lastname: Mangin
mesh_terms: D006801:Humans; D008297:Male; D008403:Mass Screening / Q000592:standards*; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control; D011785:Quality Assurance, Health Care
chemical_list: D017430:Prostate-Specific Antigen